CH679742A5 - - Google Patents
Download PDFInfo
- Publication number
- CH679742A5 CH679742A5 CH6290A CH6290A CH679742A5 CH 679742 A5 CH679742 A5 CH 679742A5 CH 6290 A CH6290 A CH 6290A CH 6290 A CH6290 A CH 6290A CH 679742 A5 CH679742 A5 CH 679742A5
- Authority
- CH
- Switzerland
- Prior art keywords
- complexes
- hydrogen
- general formula
- cations
- acyl
- Prior art date
Links
- 230000005298 paramagnetic effect Effects 0.000 claims abstract description 8
- 150000003839 salts Chemical class 0.000 claims abstract description 8
- -1 transition metal cations Chemical class 0.000 claims abstract description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 7
- 239000001257 hydrogen Substances 0.000 claims abstract description 7
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract description 7
- 150000001768 cations Chemical class 0.000 claims abstract description 6
- 229910052723 transition metal Inorganic materials 0.000 claims abstract description 6
- 238000003745 diagnosis Methods 0.000 claims abstract description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical compound [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 claims description 2
- 125000000204 (C2-C4) acyl group Chemical group 0.000 claims 1
- 239000007983 Tris buffer Substances 0.000 claims 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
- 230000005291 magnetic effect Effects 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 239000002872 contrast media Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 229910052688 Gadolinium Inorganic materials 0.000 description 2
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 2
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229940039231 contrast media Drugs 0.000 description 2
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 229910052747 lanthanoid Inorganic materials 0.000 description 2
- 150000002602 lanthanoids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- IXAZNYYEGLSHOS-UHFFFAOYSA-N 2-aminoethanol;phosphoric acid Chemical compound NCCO.OP(O)(O)=O IXAZNYYEGLSHOS-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 229960000958 deferoxamine Drugs 0.000 description 1
- 229940099217 desferal Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- RJOJUSXNYCILHH-UHFFFAOYSA-N gadolinium(3+) Chemical compound [Gd+3] RJOJUSXNYCILHH-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229960003330 pentetic acid Drugs 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- GGOZGYRTNQBSSA-UHFFFAOYSA-N pyridine-2,3-diol Chemical class OC1=CC=CN=C1O GGOZGYRTNQBSSA-UHFFFAOYSA-N 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229910001428 transition metal ion Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
Landscapes
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH6290A CH679742A5 (ja) | 1990-01-09 | 1990-01-09 | |
| AU70447/91A AU7044791A (en) | 1990-01-09 | 1991-01-08 | Transition metal complexes for magnetic resonance diagnosis |
| PCT/EP1991/000020 WO1991010454A1 (de) | 1990-01-09 | 1991-01-08 | Übergangsmetallkomplexe für die mr-diagnostik |
| EP19910901732 EP0510030A1 (de) | 1990-01-09 | 1991-01-08 | Übergangsmetallkomplexe für die mr-diagnostik |
| JP50207891A JPH05504343A (ja) | 1990-01-09 | 1991-01-08 | Ｍｒ―診断用の遷移金属錯体 |
| ZA912177A ZA912177B (en) | 1990-01-09 | 1991-03-22 | Contrast media for mr diagnostics |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH6290A CH679742A5 (ja) | 1990-01-09 | 1990-01-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH679742A5 true CH679742A5 (ja) | 1992-04-15 |
Family
ID=4178448
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH6290A CH679742A5 (ja) | 1990-01-09 | 1990-01-09 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0510030A1 (ja) |
| JP (1) | JPH05504343A (ja) |
| AU (1) | AU7044791A (ja) |
| CH (1) | CH679742A5 (ja) |
| WO (1) | WO1991010454A1 (ja) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4028139A1 (de) * | 1990-09-05 | 1992-03-12 | Hausmann Ag Labor | Verwendung der komplexe radioaktiver metallionen mit all-cis-1,3,5-triamino-2,4,6-cyclohexantriol und seinen derivaten fuer roentgendiagnostische zwecke und in der tumortherapie sowie zur herstellung von mitteln fuer roentgendiagnostische zwecke und fuer die tumortherapie |
| JP2894879B2 (ja) * | 1991-10-04 | 1999-05-24 | 日本メジフィジックス株式会社 | 診断用造影剤 |
| JP5172162B2 (ja) | 2006-08-25 | 2013-03-27 | 株式会社日立ハイテクノロジーズ | 欠陥検査装置 |
| WO2013171048A1 (en) | 2012-05-18 | 2013-11-21 | Bayer Pharma Aktiengesellschaft | Bis azainositol heavy metal complexes for x-ray imaging |
| EP2796152A1 (en) * | 2013-04-25 | 2014-10-29 | Bayer Pharma Aktiengesellschaft | Unsymmetrical Bis Azainositol Hafnium Complexes for X-Ray Imaging |
| EP2873670A1 (en) | 2013-11-14 | 2015-05-20 | Bayer Pharma Aktiengesellschaft | Bis azainositol zirconium complexes for X-ray imaging |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0169299A2 (de) * | 1981-07-24 | 1986-01-29 | Schering Aktiengesellschaft | Verwendung von paramagnetischen Komplexsalzen zur Herstellung von Mitteln für die NMR-Diagnostik |
| EP0190676A1 (de) * | 1985-02-02 | 1986-08-13 | Laboratorien Hausmann AG | All-cis-1,3,5-Triamino2,4,6-cyclohexantriol-Derivate, ihre Verwendung, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Präparate |
| EP0255471A1 (de) * | 1986-07-28 | 1988-02-03 | Schering Aktiengesellschaft | 1,4,7,10-Tetraazacyclododecan-Derivate |
-
1990
- 1990-01-09 CH CH6290A patent/CH679742A5/de not_active IP Right Cessation
-
1991
- 1991-01-08 WO PCT/EP1991/000020 patent/WO1991010454A1/de not_active Application Discontinuation
- 1991-01-08 EP EP19910901732 patent/EP0510030A1/de not_active Withdrawn
- 1991-01-08 AU AU70447/91A patent/AU7044791A/en not_active Abandoned
- 1991-01-08 JP JP50207891A patent/JPH05504343A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0169299A2 (de) * | 1981-07-24 | 1986-01-29 | Schering Aktiengesellschaft | Verwendung von paramagnetischen Komplexsalzen zur Herstellung von Mitteln für die NMR-Diagnostik |
| EP0190676A1 (de) * | 1985-02-02 | 1986-08-13 | Laboratorien Hausmann AG | All-cis-1,3,5-Triamino2,4,6-cyclohexantriol-Derivate, ihre Verwendung, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Präparate |
| EP0255471A1 (de) * | 1986-07-28 | 1988-02-03 | Schering Aktiengesellschaft | 1,4,7,10-Tetraazacyclododecan-Derivate |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0510030A1 (de) | 1992-10-28 |
| JPH05504343A (ja) | 1993-07-08 |
| WO1991010454A1 (de) | 1991-07-25 |
| AU7044791A (en) | 1991-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0071564B1 (de) | Paramagnetische Komplexsalze, deren Herstellung und Verwendung bei der NMR-Diagnostik | |
| DE69032761T2 (de) | Hydroxy-aryl metallchelate für bildformung zur nmr diagnose | |
| DE3751829T2 (de) | Anwendung von Chelat-Komplexen | |
| DE3401052C2 (de) | Diagnostische Mittel | |
| EP0124766B1 (de) | Enterales Kontrastmittel für die Kernspintomographie und dessen Herstellung | |
| DE3650572T3 (de) | Kontrastmittel zur darstellung des leber-gallensystems mittels nmr-kontrastmittel | |
| DE68920733T2 (de) | Mangan-chelate. | |
| US5087440A (en) | Heterocyclic derivatives of DTPA used for magnetic resonance imaging | |
| DE68908185T2 (de) | Chelat-zusammensetzung. | |
| EP0130934B1 (de) | Neue Komplexbildner, Komplexe und Komplexsalze | |
| DE2628517C2 (de) | Dicarbonsäure-bis(3,5-dicarbamoyl-2,4,6-trijodanilid)-Verbindungen, Verfahren zu ihrer Herstellung und Röntgenkontrastmittel | |
| US5077037A (en) | Novel compositions for magnetic resonance imaging | |
| DE69314613T3 (de) | Neues chelatisierungsmittel, komplexverbindungen, die aus diesem mittel und metallatomen aufgebaut sind, und diagnostische mittel, die diese verbindungen enthalten | |
| US5162109A (en) | Magnetic resonance imaging agents | |
| WO1994001406A1 (de) | Kontrastmittel für die mr diagnostik | |
| DE4344460A1 (de) | Metallkomplexe von dendrimeren Makromolekülen, diese enthaltende diagnostische Mittel sowie Verfahren zur Herstellung der Komplexe und Mittel | |
| DE69226022T2 (de) | Hydroxamat- und hydrazidderivate von polyaminen und ihre medizinische verwendung als chelatierende wirkstoffe | |
| DE69116637T2 (de) | Mittel zur magnetischen Resonanzabbildung | |
| DE68922218T2 (de) | Kontrastmittel für magnetische resonanzabbildung des kleinen darms und des hepatobiliaren systems. | |
| DE69009758T2 (de) | Mittel für magnetische resonanzbilderzeugung. | |
| CH679742A5 (ja) | ||
| DE10040858C2 (de) | Perfluoralkylhaltige Komplexe mit polaren Resten, Verfahren zu deren Herstellung und ihre Verwendung | |
| WO1999042139A2 (de) | Hydroxyethylstärke-konjugate, verfahren zu ihrer herstellung und diese enthaltenden pharmazeutische mittel | |
| US5858329A (en) | MRI diagnostic procedures using tripodal pyridinyl metal complexes | |
| JPH06502858A (ja) | 磁気共鳴イメージング用錯体および組成物，並びにこれらの使用法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased | ||
| PL | Patent ceased |